Get started
Author

WH Bakker

Observed names: Bakker, WH, W H Bakker, W. H. Bakker, W.H. Bakker
OpenAlex ID: A5111677028
Localisation of Endocrine-related Tumours With Radioiodinated Analogue of Somatostatin
1989 · E.P. Krenning, W.A.P. Breeman, et al. · The Lancet · 628
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
1992 · E P Krenning, W H Bakker, et al. · PubMed · 422
Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
1998 · M de Jong, W A Breeman, et al. · PubMed · 206
Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.
1999 · E P Krenning, R Valkema, et al. · PubMed · 115
Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
1999 · D J Kwekkeboom, P P Kooij, et al. · PubMed · 106
Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats.
1998 · W A Breeman, M de Jong, et al. · PubMed · 19
Phase I study of therapy with Y-90-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors.
2002 · Roelf Valkema, François Jamar, et al. · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · 18
Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas
1991 · W. Becker, J. Marienhagen, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 14
Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study
2001 · Roelf Valkema, François Jamar, et al. · DIAL (Catholic University of Leuven) · 12
Studies on radiolabeled somatostatin analogues in rats and in patients.
1996 · W A Breeman, W H Bakker, et al. · PubMed · 12
Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy
2000 · M. de Jong, M. van Hagen, et al. · Nuclear Medicine Communications · 10
Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy.
2000 · P. Jonard, François Jamar, et al. · Digital Access to Libraries · 9
[DOTA,Tyr3]octreotate, labeled with 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumors
2000 · M. de Jong, W. A.P. Breeman, et al. · Nuclear Medicine Communications · 8
Targeted radiotherapy with Y-90-DOTA-TYR3-octreotide (Y-90-SMT487; OctreoTher (TM)): A phase I study.
2000 · Roelf Valkema, François Jamar, et al. · Digital Access to Libraries · 8
Phase 1 study of peptide receptor radionuclide therapy (PRRT) with [Y-90-DOTA,Tyr(3)]octreotide in patients with somatostatin receptor positive tumors
2003 · Roelf Valkema, François Jamar, et al. · Digital Access to Libraries · 7
Peptide receptor radionuclide therapy (PRRT) with Y-90-DOTA(0),Tyr(3)-octreotide (Y-Oc) and In-111-DTPA(0)-octreotide (In-Oc): Comparison of tumor response and toxicity.
2002 · Roelf Valkema, Stanislas Pauwels, et al. · DIAL (Catholic University of Leuven) · 5
Peptide receptor therapy with 111IN-DTPA-octreotide (OC)
1997 · E.P. Krenning, R. Valkema, et al. · European Journal of Cancer · 1
In vivo somatostatin receptor imaging in lung cancer
1991 · G.S. Kho, E.P. Krenning, et al. · Lung Cancer · 1
[Receptor scintigraphy with somatostatin analog in oncology].
1990 · E P Krenning, W H Bakker, et al. · PubMed · 1
Book reviews
1997 · W. H. Bakker, L. J. Hofland, et al. · European Journal of Nuclear Medicine and Molecular Imaging
Works count: 29
Citation count: 1,603
H-index: 10
I10-index: 11
Year
Topic
Type